NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free ARCT Stock Alerts $33.15 +0.02 (+0.06%) (As of 07:23 AM ET) Add Compare Share Share Today's Range$33.15▼$33.1550-Day Range$31.72▼$42.9952-Week Range$14.62▼$43.81Volume150 shsAverage Volume413,608 shsMarket Capitalization$892.40 millionP/E RatioN/ADividend YieldN/APrice Target$56.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Arcturus Therapeutics alerts: Email Address Arcturus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside70.3% Upside$56.43 Price TargetShort InterestBearish17.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.42) to $5.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.61 out of 5 starsMedical Sector495th out of 946 stocksPharmaceutical Preparations Industry231st out of 435 stocks 3.5 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $56.43, Arcturus Therapeutics has a forecasted upside of 70.3% from its current price of $33.13.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.34% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 6.64%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 3.2 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Arcturus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows13 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 225% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.87% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($1.42) to $5.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -31.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -31.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Arcturus Therapeutics Stock (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Stock News HeadlinesMarch 17, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 16, 2024 | ca.finance.yahoo.comARCT Apr 2024 30.000 callMarch 19, 2024 | Paradigm Press (Ad)Biden out June 13?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 11, 2024 | markets.businessinsider.comThe Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 ExpertsMarch 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)March 10, 2024 | americanbankingnews.comWilliam Blair Reiterates "Outperform" Rating for Arcturus Therapeutics (NASDAQ:ARCT)March 10, 2024 | americanbankingnews.comArcturus Therapeutics (NASDAQ:ARCT) Shares Gap Down to $37.19March 9, 2024 | seekingalpha.comArcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cigna (CI) and Arcturus Therapeutics (ARCT)March 8, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comQ4 2023 Arcturus Therapeutics Holdings Inc Earnings CallMarch 8, 2024 | finance.yahoo.comArcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline DevelopmentsMarch 7, 2024 | investorplace.comARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Arcturus Therapeutics Q4 EarningsMarch 7, 2024 | businesswire.comArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressMarch 7, 2024 | finance.yahoo.comARCT Sep 2024 30.000 putMarch 6, 2024 | benzinga.comEarnings Preview: Arcturus TherapeuticsMarch 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from Arcturus Therapeutics's earningsMarch 6, 2024 | msn.comArcturus Therapeutics Q4 2023 Earnings PreviewMarch 2, 2024 | investing.comArcturus Therapeutics Holdings Inc (ARCT)February 26, 2024 | investorplace.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 26, 2024 | finance.yahoo.comArcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceFebruary 26, 2024 | businesswire.comArcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceFebruary 22, 2024 | businesswire.comArcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic FibrosisFebruary 21, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024February 20, 2024 | investorplace.com3 Tech Stocks That Could Be Multibaggers in the Making: February EditionSee More Headlines Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/19/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$56.43 High Stock Price Target$90.00 Low Stock Price Target$36.00 Potential Upside/Downside+70.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-15.65% Pretax Margin-16.72% Return on Equity-18.22% Return on Assets-11.95% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.72 Sales & Book Value Annual Sales$169.93 million Price / Sales5.25 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book3.18Miscellaneous Outstanding Shares26,920,000Free Float23,201,000Market Cap$892.40 million OptionableOptionable Beta2.64 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 52)Founder, President, CEO & Director Comp: $1.13MMr. Andrew H. Sassine MBA (Age 60)CFO & Director Comp: $826.88kMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Lance KurataChief Legal OfficerMs. Natash O. BowmanChief Human Resources OfficerMr. Kevin T. SkolChief Business OfficerDr. Juergen Froehlich FCPh (Age 68)M.D., MBA, Chief Medical Officer Dr. Igor Smolenov M.D.Ph.D., Chief Development OfficerMore ExecutivesKey CompetitorsGeronNASDAQ:GERNTango TherapeuticsNASDAQ:TNGXZentalis PharmaceuticalsNASDAQ:ZNTLCentessa PharmaceuticalsNASDAQ:CNTAArcutis BiotherapeuticsNASDAQ:ARQTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 51,537 shares on 3/11/2024Ownership: 5.458%Wellington Management Group LLPBought 17,491 shares on 3/5/2024Ownership: 0.228%Goldman Sachs Group Inc.Bought 69,156 shares on 3/1/2024Ownership: 1.552%Price T Rowe Associates Inc. MDBought 360 shares on 2/16/2024Ownership: 0.060%Public Employees Retirement System of OhioBought 2,820 shares on 2/16/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions ARCT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcturus Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARCT shares. View ARCT analyst ratings or view top-rated stocks. What is Arcturus Therapeutics' stock price target for 2024? 7 equities research analysts have issued 12 month target prices for Arcturus Therapeutics' stock. Their ARCT share price targets range from $36.00 to $90.00. On average, they predict the company's stock price to reach $56.43 in the next year. This suggests a possible upside of 70.3% from the stock's current price. View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts. How have ARCT shares performed in 2024? Arcturus Therapeutics' stock was trading at $31.53 at the beginning of 2024. Since then, ARCT stock has increased by 5.1% and is now trading at $33.13. View the best growth stocks for 2024 here. Are investors shorting Arcturus Therapeutics? Arcturus Therapeutics saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 4,220,000 shares, a drop of 6.6% from the February 14th total of 4,520,000 shares. Based on an average daily volume of 419,100 shares, the days-to-cover ratio is presently 10.1 days. Currently, 17.3% of the company's stock are sold short. View Arcturus Therapeutics' Short Interest. When is Arcturus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ARCT earnings forecast. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.65. The biotechnology company had revenue of $2.44 million for the quarter, compared to analyst estimates of $26.70 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative trailing twelve-month return on equity of 17.91%. During the same period last year, the firm posted ($0.92) EPS. What ETFs hold Arcturus Therapeutics' stock? ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Morningstar US Small Growth (MSGR), Subversive Mental Health ETF (SANE), ARK Genomic Revolution ETF (ARKG), Amplify Treatments, Testing and Advancements ETF (GERM), WisdomTree BioRevolution Fund (WDNA), AXS Green Alpha ETF (NXTE), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Jacob Forward ETF (JFWD). What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (7.66%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.46%), Sumitomo Mitsui Trust Holdings Inc. (4.94%), Nikko Asset Management Americas Inc. (4.94%) and Dimensional Fund Advisors LP (4.08%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARCT) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe world’s greatest investmentPorter & CompanyBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.